Immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in patients receiving secukinumab: a literature review

• Egile Nagusiak: Paolo Gisondi (Egilea), David Simon (Egilea), Ivette Alarcon (Egilea), Effie Pournara (Egilea), Lluís Puig (Egilea)
• Formatua: Liburua
• Argitaratua: Taylor & Francis Group, 2023-12-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Purpose: There is a paucity of evidence on the impact of immune-mediated inflammatory disease (IMID) treatments on the immunogenicity of SARS-CoV-2 vaccination. The purpose of this literature review is to address the question of whether patients with IMIDs receiving secukinumab, a fully human anti-i...